Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

BACKGROUND: Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorff, Tanya, Hirasawa, Yosuke, Acoba, Jared, Pagano, Ian, Tamura, David, Pal, Sumanta, Zhang, Minlu, Waitz, Rebecca, Dhal, Abhilash, Haynes, Winston, Shon, John, Scholz, Mark, Furuya, Hideki, Chan, Owen T M, Huang, Jeffrey, Rosser, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356194/
https://www.ncbi.nlm.nih.gov/pubmed/34376554
http://dx.doi.org/10.1136/jitc-2021-002931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356194/
https://www.ncbi.nlm.nih.gov/pubmed/34376554
http://dx.doi.org/10.1136/jitc-2021-002931

Ejemplares similares